IVERIC bio (NASDAQ:ISEE) reported Q2 EPS of ($0.41), $0.11 worse than the analyst estimate of ($0.30).
As of June 30, 2022, the Company had $312 million in cash, cash equivalents and available for sale securities.
IVERIC bio (NASDAQ:ISEE) reported Q2 EPS of ($0.41), $0.11 worse than the analyst estimate of ($0.30).
As of June 30, 2022, the Company had $312 million in cash, cash equivalents and available for sale securities.